VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Study Type
Observational [Patient Registry]
Study Phase
Phase 3
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Intervention
Name: Thoracoscopy/VATS
Type: Procedure
Overall Status
Recruiting
Summary
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.
Detailed Description
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.This is a multicenter, prospective study, aimed To evaluate the short-term and long- term outcome of VATS major lung resection for early stage lung cancer. Patients will be followed up every 3 months for 3 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

Preoperative criteria:

i) non-small cell lung cancer is suspected, ii) clinical stage I/II (3) Intraoperative criteria: i) Histologically confirmed NSCLC, ii) resected by VATS or converted open lobectomy,sleeve lobectomy or pneumonectomy and nodal dissection/sampling.

(4) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed).

(5) No prior chemotherapy or radiation therapy for any malignant diseases. (6) Expected postoperative FEV1.0>=800 mL and PaO2>=65 torr. (7) Performance status of 0 or 1. (8) Sufficient organ functions. (9) Written informed consent.

Exclusion Criteria:

1. Active bacterial or fungous infection.

2. Simultaneous or metachronous (within the past 5 years) double cancers.

3. Women during pregnancy or breast-feeding.

4. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema.

5. Psychosis.

6. Systemic steroids medication.

7. Uncontrollable diabetes mellitus.

8. Uncontrollable hypertension.

9. History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.
Locations
Beijing Anzhen Hospital
Beijing, Beijing, China
Status: Not yet recruiting
Contact: Songlei Ou
Beijing Cancer Hospital
Beijing, Beijing, China
Status: Not yet recruiting
Contact: Keneng Chen
Beijing Chao-Yang Hospital
Beijing, Beijing, China
Status: Not yet recruiting
Contact: Hui Li
Beijing Haidian Hospital
Beijing, Beijing, China
Status: Recruiting
Contact: Yuqing Huang
Beijing Friendship Hospital
Beijing, China
Status: Not yet recruiting
Contact: Zhi Gao
Peking university people's hospital
Beijing, China
Status: Recruiting
Contact: Jun Wang, MD
Start Date
September 2014
Completion Date
June 2017
Sponsors
Peking University People's Hospital
Source
Peking University People's Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page